<DOC>
	<DOCNO>NCT02951195</DOCNO>
	<brief_summary>This Phase 2 , randomize , double blind , placebo active-controlled , parallel group , multicenter study design evaluate safety tolerability VX-152 Triple Combination ( TC ) tezacaftor ( TEZ ; VX-661 ) ivacaftor ( IVA ; VX-770 ) subject cystic fibrosis ( CF ) heterozygous F508del mutation minimal function ( MF ) CFTR mutation likely respond TEZ and/or IVA therapy ( F508del/MF ) , homozygous F508del mutation CF transmembrane conductance regulator ( CFTR ) gene ( F508del/F508del ) .</brief_summary>
	<brief_title>A Study Evaluating Safety VX-152 Combination Therapy Adults With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Willing able comply schedule visit , treatment pan , study restriction , laboratory test , contraceptive guideline , study procedure . Body weight ≥35 kg . Sweat chloride value ≥ 60 mmol/L test result obtain screen . Subjects must eligible CFTR genotype : Cohorts 1A , 1B , 1C : Heterozygous F508del minimal function mutation know predict respond TEZ and/or IVA . Cohorts 2A , 2B : Homozygous F508del . Subjects must FEV1 ≥40 % ≤90 % predict normal age , sex , height Screening Visit . Stable CF disease judge investigator . Willing remain stable CF medication regimen plan end treatment applicable Safety Followup Visit . History comorbidity opinion investigator might confound result study pose additional risk administer study drug subject . History cirrhosis portal hypertension . Risk factor Torsade de Pointes . History hemolysis . Glucose6phosphate dehydrogenase ( G6PD ) deficiency assess Screening . Clinically significant abnormal laboratory value screen . An acute upper low respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 28 day first dose study drug . Lung infection organisms associate rapid decline pulmonary status . An acute illness relate CF within 14 day first dose study drug . A standard digital ECG demonstrate QTc &gt; 450 msec screening . History solid organ hematological transplantation . History evidence cataract lens opacity determine clinically significant ophthalmologist optometrist , base ophthalmologic examination Screening Period . History alcohol drug abuse past year , include limited , cannabis , cocaine , opiates , deem investigator . Ongoing prior participation investigational drug study certain exception . Use commercially available CFTR modulator within 14 day screen ( applies Cohorts 1A , 1B , 1C ) . Pregnant nursing female : Females childbearing potential must negative pregnancy test screen Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>